House File 2377 S-5233 Amend House File 2377, as amended, passed, and reprinted by 1 the House, as follows: 2 1. Page 23, after line 29 by inserting: 3 < DIVISION ___ 4 MEDICAL CANNABIDIOL 5 Sec. ___. Section 124E.2, subsection 2, Code 2018, is 6 amended by adding the following new paragraphs: 7 NEW PARAGRAPH . j. Glaucoma. 8 NEW PARAGRAPH . k. Ehlers-Danlos syndrome. 9 NEW PARAGRAPH . l. Post-traumatic stress disorder. 10 NEW PARAGRAPH . m. Tourette’s syndrome. 11 NEW PARAGRAPH . n. Muscular dystrophy. 12 NEW PARAGRAPH . o. Huntington’s disease. 13 NEW PARAGRAPH . p. Alzheimer’s disease. 14 NEW PARAGRAPH . q. Complex regional pain syndrome, types I 15 and II. 16 NEW PARAGRAPH . r. Rheumatoid arthritis. 17 NEW PARAGRAPH . s. Polyarteritis nodosa. 18 NEW PARAGRAPH . t. Hepatitis C. 19 NEW PARAGRAPH . u. Any other chronic or debilitating disease 20 or medical condition or its medical treatment approved by the 21 department pursuant to rule. 22 Sec. ___. Section 124E.2, subsection 6, Code 2018, is 23 amended to read as follows: 24 6. “Medical cannabidiol” means any pharmaceutical 25 grade cannabinoid found in the plant Cannabis sativa L. or 26 Cannabis indica or any other preparation thereof that has 27 a tetrahydrocannabinol level of no more than three percent 28 and that is delivered in a form recommended by the medical 29 cannabidiol board, approved by the board of medicine, and 30 adopted by the department pursuant to rule. 31 Sec. ___. Section 124E.5, subsection 6, Code 2018, is 32 amended by striking the subsection. > 33 2. By renumbering as necessary. 34 -1- HF2377.5202 (2) 87 ss/rh 1/ 2 #1.